



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	. F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/691,330	10/691,330 10/22/2003		Istvan Boldogh	265.00390101	1384
26813	7590	02/08/2005		EXAMINER	
MUETIN P.O. BOX	•	CH & GEBHARDT	KAM, CHIH MIN		
MINNEAPOLIS, MN 55458				ART UNIT	PAPER NUMBER
	,			1653	

DATE MAILED: 02/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	_
Office Action Summary		10/691,330	BOLDOGH ET AL.	
		Examiner	Art Unit	_
		Chih-Min Kam	1653	
Period fo	The MAILING DATE of this communication apport	pears on the cover sheet with the	correspondence address	
THE - Exte after - If the - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR REPLIMAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a replication of the provision of the provision of the provision of the period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be till by within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a, cause the application to become ABANDONE	mely filed ys will be considered timely. the mailing date of this communication. ED (35 U.S.C. § 133).	
Status				
1)	Responsive to communication(s) filed on			
2a) <u></u>	This action is FINAL . 2b) This	action is non-final.		
3)□	Since this application is in condition for allowardlosed in accordance with the practice under E	•		
Disposit	ion of Claims			
5) 6) 7)	Claim(s) 1-24 is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-24 are subject to restriction and/or	wn from consideration.		
Applicat	ion Papers			
9)[The specification is objected to by the Examine	er.		
10)[The drawing(s) filed on is/are: a) acc	epted or b) objected to by the	Examiner.	
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).	
	Replacement drawing sheet(s) including the correct		• •	
11)	The oath or declaration is objected to by the Ex	kaminer. Note the attached Office	Action or form PTO-152.	•
Priority ι	under 35 U.S.C. § 119			
a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau See the attached detailed Office action for a list	is have been received. Is have been received in Applications In the second seco	ion No ed in this National Stage	
A440 - b	Ma)			
Attachmen 1) Notice	t(s) e of References Cited (PTO-892)	4) Interview Summary	(PTO 412)	
2) 🔲 Notic 3) 🔲 Infor	te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	Paper No(s)/Mail D		

Application/Control Number: 10/691,330

Art Unit: 1653

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U. S. C. 121:
 - I. claims 1-15, drawn to a method of inhibiting apoptosis or protecting against DNA damage in a cell, comprising contacting the cell with an apoptosis inhibitor of colostrinin, a constituent peptide thereof, an active analog thereof or a combination thereof, classified in class 514, subclass 2, and 424, subclass 9.1.
 - II. claims 16-19, drawn to a method of reducing the toxic effect of β-amyloid on a cell, comprising contacting the cell with a compound of colostrinin, a constituent peptide thereof, an active analog thereof or a combination thereof, classified in class 514, subclass 2, and 424, subclass 9.1.
 - III. claims 20-23, drawn to a method of reducing the toxic effect of retinoic acid on a cell, comprising contacting the cell with a compound of colostrinin, a constituent peptide thereof, an active analog thereof or a combination thereof, classified in class 514, subclass 2, and 424, subclass 9.1.
 - IV. claim 24, drawn to use of a compound of colostrinin, a constituent peptide thereof, an active analog thereof or a combination thereof in the manufacture of a medicament, classified in class 514, subclass 2, and 530, subclass 350.

 Should Group I be elected, applicant is required to select one (1) specific constituent peptide of colostrinin from claim 6 or 7. Each constituent peptide, which contains different amino acid sequence and has different effect, is considered patentably distinct. This is not species election.

Application/Control Number: 10/691,330

Art Unit: 1653

2. The inventions are distinct, each from the other because of the following reasons:

The methods of Inventions I, II, III and IV are distinct from each other because the method steps and outcomes are wholly different among Inventions I, II, III and IV.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter, and because inventions I-IV require different searches but are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1653

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.

Patent Examiner

CMK

February 5, 2005